{"id":7576,"date":"2025-04-07T07:44:28","date_gmt":"2025-04-07T14:44:28","guid":{"rendered":"https:\/\/highfieldbio.com\/?p=7576"},"modified":"2025-04-18T06:41:09","modified_gmt":"2025-04-18T13:41:09","slug":"studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532","status":"publish","type":"post","link":"https:\/\/highfieldbio.com\/zh\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/","title":{"rendered":"HighField Biopharmaceuticals \u5df2\u83b7\u51c6\u8fdb\u884c HF1K16\uff08\u4e00\u79cd\u72ec\u7279\u7684\u9ad3\u7cfb\u7ec6\u80de\u5b9a\u5411\u514d\u75ab\u8c03\u8282\u5242\uff09\u7684 2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5176 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5c06\u4e8e AACR 2025 \u4f1a\u8bae\u4e0a\u516c\u5e03"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"7576\" class=\"elementor elementor-7576\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7c3df96 elementor-section-boxed elementor-section-height-default elementor-section-height-default smart-sticky-default\" data-id=\"7c3df96\" data-element_type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f09d554\" data-id=\"f09d554\" data-element_type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-33706a9 elementor-widget elementor-widget-spacer\" data-id=\"33706a9\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7f9ed22 elementor-widget elementor-widget-udesign_widget_heading\" data-id=\"7f9ed22\" data-element_type=\"widget\" data-widget_type=\"udesign_widget_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"title-wrapper  title-cross title-center\"><p class=\"title elementor-heading-title\">2025 \u5e74 4 \u6708 7 \u65e5 | HighField Bio \u65b0\u95fb\u7a3f<\/p><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b2ac3db elementor-widget elementor-widget-spacer\" data-id=\"b2ac3db\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ac618a2 elementor-widget elementor-widget-udesign_widget_heading\" data-id=\"ac618a2\" data-element_type=\"widget\" data-widget_type=\"udesign_widget_heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"title-wrapper  title-center\"><h2 class=\"title elementor-heading-title\">HighField Biopharmaceuticals \u5df2\u83b7\u51c6\u8fdb\u884c HF1K16\uff08\u4e00\u79cd\u72ec\u7279\u7684\u9ad3\u7cfb\u7ec6\u80de\u5b9a\u5411\u514d\u75ab\u8c03\u8282\u5242\uff09\u7684 2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5176 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5c06\u4e8e AACR 2025 \u4f1a\u8bae\u4e0a\u516c\u5e03<\/h2><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-027104d alpha-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default smart-sticky-default\" data-id=\"027104d\" data-element_type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-a846582\" data-id=\"a846582\" data-element_type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ed689c6 elementor-widget elementor-widget-text-editor\" data-id=\"ed689c6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\"><strong><em>HF1K16\uff08K16\uff09\u7b2c 1 \u9636\u6bb5\u8bd5\u9a8c\u7684\u9876\u7ebf\u6570\u636e\u5c06\u7531\u9996\u5e2d\u6267\u884c\u5b98\u517c\u79d1\u5b66\u521b\u59cb\u4eba\u5f90\u5b87\u5b8f\u535a\u58eb\u5728 2025 \u5e74 4 \u6708 25 \u65e5\u81f3 30 \u65e5\u5728\u829d\u52a0\u54e5\u4e3e\u884c\u7684\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\u5e74\u4f1a\u4e0a\u516c\u5e03\u3002<\/em><\/strong><\/p><p style=\"text-align: center;\"><strong><em>\u7b2c 2 \u9636\u6bb5\u7814\u7a76\u5c06\u8bc4\u4f30 K16 \u4e0e <\/em><em>\u5316\u7597<\/em><em> \u9002\u7528\u4e8e\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5b9e\u4f53\u80bf\u7624\u60a3\u8005\uff0c\u5305\u62ec\u8111\u764c\u3002 <\/em><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e59da4e elementor-widget-laptop__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e59da4e\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u4e2d\u56fd\u676d\u5dde\uff082025 \u5e74 4 \u6708 7 \u65e5\uff09\u2014\u2014HighField Biopharmaceuticals \u662f\u4e00\u5bb6\u4f7f\u7528\u8102\u8d28\u7597\u6cd5\u6cbb\u7597\u764c\u75c7\u548c\u5176\u4ed6\u75be\u75c5\u7684\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\uff0c\u8be5\u516c\u53f8\u4eca\u5929\u5ba3\u5e03\u5176\u65b0\u836f\u4e34\u5e8a\u8bd5\u9a8c (IND) \u7533\u8bf7\u5df2\u83b7\u5f97\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u7684\u6279\u51c6\uff0c\u5c06\u5728\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u80f0\u817a\u764c\u548c\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u4ee5\u53ca\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u60a3\u8005\u4e2d\u8fdb\u884c HF1K16 (K16) \u7684 2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002K16 \u662f\u4e00\u79cd\u521b\u65b0\u7684\u514d\u75ab\u8c03\u8282\u8102\u8d28\u4f53\u836f\u7269\uff0c\u9776\u5411\u80bf\u7624\u5fae\u73af\u5883\u4e2d\u7684\u9ad3\u6e90\u6027\u6291\u5236\u7ec6\u80de (MDSC)<\/p><p>\u8be5\u7b2c\u4e8c\u9636\u6bb5\u7814\u7a76\u662f\u5728\u4e2d\u56fd\u5bf9\u590d\u53d1\u6027\u548c\u96be\u6cbb\u6027\u80f6\u8d28\u7624\u4ee5\u53ca\u5305\u62ec\u80c3\u764c\u3001\u7ed3\u76f4\u80a0\u764c\u3001\u809d\u764c\u3001\u80ba\u764c\u548c\u5375\u5de2\u764c\u5728\u5185\u7684\u8f6c\u79fb\u6027\u5b9e\u4f53\u7624\u60a3\u8005\u8fdb\u884c\u7684 K16 \u7b2c\u4e00\u9636\u6bb5\u8bd5\u9a8c\u53d6\u5f97\u79ef\u6781\u7ed3\u679c\u4e4b\u540e\u8fdb\u884c\u7684\u3002<\/p><p>HighField \u9996\u5e2d\u6267\u884c\u5b98\u517c\u79d1\u5b66\u521b\u59cb\u4eba\u5f90\u5b87\u5b8f\u535a\u58eb\u5c06\u5728 <a href=\"https:\/\/www.aacr.org\/meeting\/aacr-annual-meeting-2025\/\">\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a<\/a> 2025 \u5e74 4 \u6708 25 \u65e5\u81f3 30 \u65e5\u5728\u829d\u52a0\u54e5\u4e3e\u884c\u7684\u5e74\u5ea6\u4f1a\u8bae\u3002\u4ee5\u4e0b\u662f\u6f14\u8bb2\u7684\u8be6\u7ec6\u4fe1\u606f\uff1a<\/p><p style=\"padding-left: 40px;\"><strong>\u6807\u9898<\/strong>\uff1a\u5b9e\u4f53\u7624\u548c\u8111\u7624\u60a3\u8005\u7684\u9ad3\u7cfb\u7ec6\u80de\u9776\u5411\u514d\u75ab\u8c03\u8282\uff1aNCT05388487 \u7b2c 1 \u9636\u6bb5\u7814\u7a76\u6570\u636e\u7684\u5206\u6790\u3002<br \/><strong style=\"background-color: var(--alpha-page-wrapper-bg-color); letter-spacing: var(--alpha-body-letter-spacing); text-transform: var(--alpha-body-text-transform);\">\u6570\u5b57<\/strong><span style=\"background-color: var(--alpha-page-wrapper-bg-color); letter-spacing: var(--alpha-body-letter-spacing); text-transform: var(--alpha-body-text-transform);\">\uff1aLB205\u3002<br \/><\/span><strong>\u4f1a\u8bae<\/strong>\uff1a\u6700\u65b0\u7814\u7a76\uff1a\u4e34\u5e8a\u7814\u7a76 1<br \/><strong>\u6f14\u8bb2\u65f6\u95f4<\/strong>\uff1a2025\u5e744\u670828\u65e5\u4e0b\u53482:00-\u4e0b\u53485:00<\/p><p>K16 \u662f\u4e00\u79cd\u72ec\u7279\u7684\u5168\u53cd\u5f0f\u7ef4\u7532\u9178 (ATRA) \u8102\u8d28\u4f53\u7ed3\u6784\uff0cATRA \u662f\u7ef4\u751f\u7d20 A \u7684\u4ee3\u8c22\u7269\uff0c\u901a\u8fc7\u8f93\u6ce8\u7ed9\u836f\u3002\u5f53\u8102\u8d28\u4f53\u7ed3\u6784\u6e17\u5165\u80bf\u7624\u5fae\u73af\u5883\u65f6\uff0cATRA \u88ab\u91ca\u653e\u5e76\u542f\u52a8 MDSC \u7684\u5206\u5316\u548c\u6210\u719f\u3002<\/p><p>MDSC \u662f\u672a\u6210\u719f\u7684\u9ad3\u7cfb\u7ec6\u80de\uff0c\u5728\u764c\u75c7\u53d1\u5c55\u548c\u8fdb\u5c55\u4e2d\u6784\u6210\u514d\u75ab\u6291\u5236\u73af\u5883\u65b9\u9762\u53d1\u6325\u7740\u91cd\u8981\u4f5c\u7528\u3002K16 \u4fc3\u8fdb MDSC \u5206\u5316\u4e3a\u529f\u80fd\u6027\u7ec6\u80de\uff0c\u4f8b\u5982\u6811\u7a81\u72b6\u7ec6\u80de\uff0c\u7136\u540e\u6811\u7a81\u72b6\u7ec6\u80de\u4f1a\u53ec\u5524 T \u7ec6\u80de\u6765\u653b\u51fb\u764c\u75c7\u3002<\/p><p>\u8fd9\u9879 2 \u671f\u5f00\u653e\u6807\u7b7e\u3001\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\u5c06\u8bc4\u4f30 K16 \u4e0e\u6807\u51c6\u6cbb\u7597 (SOC) \u5316\u7597\u8054\u5408\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c (NSCLC)\u3001\u80f0\u817a\u764c\u548c\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002K16 \u72ec\u7279\u7684\u5b89\u5168\u6027\u548c\u4f5c\u7528\u673a\u5236\u4e0e\u73b0\u6709\u7684\u514d\u75ab\u6cbb\u7597\u836f\u7269\u4e0d\u540c\uff0c\u8868\u660e\u4e0e\u5316\u7597\u8054\u5408\u4f7f\u7528\u65f6\uff0c\u6297\u80bf\u7624\u529f\u6548\u751a\u81f3\u53ef\u80fd\u9ad8\u4e8e K16 \u4f5c\u4e3a\u5355\u4e00\u7597\u6cd5\u7684 1 \u671f\u8bd5\u9a8c\u7ed3\u679c\u3002HighField \u5728 AACR \u4f1a\u8bae\u4e0a\u4ecb\u7ecd\u7684\u5c31\u662f 1 \u671f\u7814\u7a76\u7684\u6570\u636e\u3002<\/p><p><strong>\u5173\u4e8e HighField \u751f\u7269\u5236\u836f<\/strong><\/p><p>Highfield \u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u9488\u5bf9\u514d\u75ab\u80bf\u7624\u5b66\u548c\u57fa\u56e0\u6cbb\u7597\u7684\u8102\u8d28\u4f53\u7ed3\u6784\u7684\u65b0\u5e94\u7528\u3002HighField \u5728\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u4e3b\u5bfc\u4ea7\u54c1\u662f K1\uff0c\u6e90\u81ea\u5176 ADCplex<sup>\u5546\u6807<\/sup> \u5e73\u53f0\uff0c\u968f\u540e\u662f HF50\uff0c\u6e90\u81ea\u5176 TCEplex<sup>\u5546\u6807 <\/sup>\u5e73\u53f0\u3002\u8be5\u516c\u53f8\u7684\u4ea7\u54c1\u7ebf\u8fd8\u5305\u62ec K16\uff0c\u4e00\u79cd\u836f\u7269\u5305\u88f9\u7684\u514d\u75ab\u8c03\u8282\u8102\u8d28\u4f53\uff0c\u9776\u5411\u9aa8\u9ad3\u6765\u6e90\u7684\u6291\u5236\u7ec6\u80de\uff0c\u7528\u4e8e\u96be\u6cbb\u6027\u764c\u75c7\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff1b\u4ee5\u53ca\u6e90\u81ea\u5176 tLNPplex\u2122 \u5e73\u53f0\u7684 HFG1\uff0c\u7528\u4e8e GLP-1R \u6fc0\u52a8\u5242\u7684 mRNA \u8868\u8fbe\uff0c\u7528\u4e8e\u51cf\u80a5\u548c\u6cbb\u7597\u7cd6\u5c3f\u75c5\u3002\u6709\u5173\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95ee <a href=\"http:\/\/highfieldbio.com\/zh\/\">highfieldbio.com<\/a><\/p><p><strong>\u5a92\u4f53\u8054\u7cfb\u65b9\u5f0f\uff1a<\/strong><br \/>\u4e39\u00b7\u57c3\u62c9\u7c73\u5b89<br \/>Opus \u751f\u7269\u6280\u672f\u901a\u8baf<br \/><a href=\"mailto:danieleramian@comcast.net\">danieleramian@comcast.net<\/a><\/p><p>425-306-8716<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>HighField Biopharmaceuticals \u5df2\u83b7\u51c6\u8fdb\u884c\u5176\u72ec\u7279\u7684\u9ad3\u7cfb\u7ec6\u80de\u514d\u75ab\u8c03\u8282\u5242 HF1K16 \u7684 2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5176 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5c06\u4e8e AACR 2025 \u4f1a\u8bae\u4e0a\u516c\u5e03\u3002\u8be5\u516c\u53f8\u9996\u5e2d\u6267\u884c\u5b98\u517c\u79d1\u5b66\u521b\u59cb\u4eba\u5f90\u5b87\u7ea2\u535a\u58eb\u5c06\u5728\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a (AACR) \u4e0a\u516c\u5e03 HF1K16 (K16) 1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u4e3b\u8981\u6570\u636e [\u2026]<\/p>","protected":false},"author":1,"featured_media":7594,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[22],"tags":[],"class_list":["post-7576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting - HighField Biopharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/highfieldbio.com\/zh\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting - HighField Biopharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting Topline data from the Phase 1 trial of HF1K16 (K16) will be presented by CEO and Scientific Founder Yuhong Xu, Ph.D, at the American Association for Cancer Research [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/highfieldbio.com\/zh\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\" \/>\n<meta property=\"og:site_name\" content=\"HighField Biopharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T14:44:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-18T13:41:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"PJWCreative\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\"},\"author\":{\"name\":\"PJWCreative\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\"},\"headline\":\"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting\",\"datePublished\":\"2025-04-07T14:44:28+00:00\",\"dateModified\":\"2025-04-18T13:41:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\"},\"wordCount\":568,\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg\",\"articleSection\":[\"Press Release\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\",\"url\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\",\"name\":\"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting - HighField Biopharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/highfieldbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg\",\"datePublished\":\"2025-04-07T14:44:28+00:00\",\"dateModified\":\"2025-04-18T13:41:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/highfieldbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/highfieldbio.com\/#website\",\"url\":\"https:\/\/highfieldbio.com\/\",\"name\":\"HighField Bio\",\"description\":\"Lipid-based Therapeutics Targeting the Tumor Microenvironment\",\"publisher\":{\"@id\":\"https:\/\/highfieldbio.com\/#organization\"},\"alternateName\":\"HighField Biopharmaceuticals\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/highfieldbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/highfieldbio.com\/#organization\",\"name\":\"HighField Biopharmaceuticals, Inc.\",\"alternateName\":\"HighField Bio\",\"url\":\"https:\/\/highfieldbio.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"contentUrl\":\"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png\",\"width\":1500,\"height\":494,\"caption\":\"HighField Biopharmaceuticals, Inc.\"},\"image\":{\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/highfield-biopharma\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0\",\"name\":\"PJWCreative\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g\",\"caption\":\"PJWCreative\"},\"sameAs\":[\"https:\/\/highfieldbio.com\"],\"url\":\"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HighField Biopharmaceuticals \u83b7\u6279\u5f00\u5c55 HF1K16\uff08\u4e00\u79cd\u72ec\u7279\u7684\u9ad3\u7cfb\u7ec6\u80de\u5b9a\u5411\u514d\u75ab\u8c03\u8282\u5242\uff09\u7684 2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5c06\u4e8e AACR 2025 \u4f1a\u8bae\u4e0a\u516c\u5e03 - HighField Biopharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/highfieldbio.com\/zh\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/","og_locale":"zh_CN","og_type":"article","og_title":"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting - HighField Biopharmaceuticals","og_description":"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting Topline data from the Phase 1 trial of HF1K16 (K16) will be presented by CEO and Scientific Founder Yuhong Xu, Ph.D, at the American Association for Cancer Research [&hellip;]","og_url":"https:\/\/highfieldbio.com\/zh\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/","og_site_name":"HighField Biopharmaceuticals","article_published_time":"2025-04-07T14:44:28+00:00","article_modified_time":"2025-04-18T13:41:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg","type":"image\/jpeg"}],"author":"PJWCreative","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#article","isPartOf":{"@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/"},"author":{"name":"PJWCreative","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0"},"headline":"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting","datePublished":"2025-04-07T14:44:28+00:00","dateModified":"2025-04-18T13:41:09+00:00","mainEntityOfPage":{"@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/"},"wordCount":568,"publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"image":{"@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg","articleSection":["Press Release"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/","url":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/","name":"HighField Biopharmaceuticals \u83b7\u6279\u5f00\u5c55 HF1K16\uff08\u4e00\u79cd\u72ec\u7279\u7684\u9ad3\u7cfb\u7ec6\u80de\u5b9a\u5411\u514d\u75ab\u8c03\u8282\u5242\uff09\u7684 2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c1 \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5c06\u4e8e AACR 2025 \u4f1a\u8bae\u4e0a\u516c\u5e03 - HighField Biopharmaceuticals","isPartOf":{"@id":"https:\/\/highfieldbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage"},"image":{"@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage"},"thumbnailUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg","datePublished":"2025-04-07T14:44:28+00:00","dateModified":"2025-04-18T13:41:09+00:00","breadcrumb":{"@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#primaryimage","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_AACR2025.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/highfieldbio.com\/2025\/04\/07\/studies-by-highfield-biopharmaceuticals-show-advantages-of-lipid-structure-design-for-applying-lnp-non-viral-gene-therapies-to-complex-diseases-duplicate-7532\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/highfieldbio.com\/"},{"@type":"ListItem","position":2,"name":"HighField Biopharmaceuticals\u2019 Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting"}]},{"@type":"WebSite","@id":"https:\/\/highfieldbio.com\/#website","url":"https:\/\/highfieldbio.com\/","name":"\u9ad8\u7530\u751f\u7269","description":"\u9488\u5bf9\u80bf\u7624\u5fae\u73af\u5883\u7684\u8102\u8d28\u7597\u6cd5","publisher":{"@id":"https:\/\/highfieldbio.com\/#organization"},"alternateName":"HighField Biopharmaceuticals","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/highfieldbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/highfieldbio.com\/#organization","name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f\u6709\u9650\u516c\u53f8","alternateName":"HighField Bio","url":"https:\/\/highfieldbio.com\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","contentUrl":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2021\/07\/HIGHfield_logo_horizontal_FINAL_trans.png","width":1500,"height":494,"caption":"HighField Biopharmaceuticals, Inc."},"image":{"@id":"https:\/\/highfieldbio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/highfield-biopharma"]},{"@type":"Person","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/7ec00570bf3fa5a022cd1b08bda3b0f0","name":"PJW\u521b\u610f","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/highfieldbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7558191085f3c167c2c5972a9ba86696e53fc4dec7eeb7b3e0cc15866c48b55f?s=80&d=mm&r=g","caption":"PJWCreative"},"sameAs":["https:\/\/highfieldbio.com"],"url":"https:\/\/highfieldbio.com\/zh\/author\/pjwcreative\/"}]}},"_links":{"self":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/comments?post=7576"}],"version-history":[{"count":18,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7576\/revisions"}],"predecessor-version":[{"id":7597,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/posts\/7576\/revisions\/7597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media\/7594"}],"wp:attachment":[{"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/media?parent=7576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/categories?post=7576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/highfieldbio.com\/zh\/wp-json\/wp\/v2\/tags?post=7576"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}